

**Supplementary Table 1: Additional clinical characteristics of the cohort**

Characteristic	Negative, N = 97 <sup>1</sup>	COVID-19, N = 330 <sup>1</sup>	p-value <sup>2</sup>
<b>Laboratories</b>			
White blood cell	7.6 (4.9, 11.6)	6.3 (4.6, 8.6)	<b>0.015</b>
Neutrophils	4.9 (2.9, 9.0)	4.8 (3.2, 7.0)	0.8
Hemoglobin	10.80 (9.00, 13.00)	13.00 (11.80, 14.20)	<b>&lt;0.001</b>
Neutrophil/Lymphocytes	5 (3, 9)	6 (4, 10)	0.2
Partial thromboplastin time	30.2 (27.9, 33.8)	31.8 (29.4, 34.1)	0.11
Prothrombin time	13.35 (11.85, 15.80)	13.45 (12.60, 14.47)	0.5
Fibrinogen	434 (369, 454)	461 (394, 628)	0.4
Albumin	3.10 (2.50, 3.70)	3.00 (2.60, 3.40)	0.14
Total bilirubin	0.50 (0.30, 0.85)	0.60 (0.40, 0.80)	0.4
Lactate dehydrogenase	328 (218, 480)	408 (308, 521)	0.092
Creatinine	1.01 (0.75, 1.38)	0.94 (0.76, 1.23)	0.5
Lactate	1.30 (1.00, 1.87)	1.17 (0.88, 1.65)	0.2
Glucose	111 (93, 144)	111 (95, 146)	0.6
Erythrocyte sedimentation rate	46 (30, 60)	63 (40, 86)	0.1
PH	7.45 (7.45, 7.51)	7.38 (7.32, 7.43)	<b>0.003</b>
PaO <sub>2</sub>	112 (86, 152)	39 (25, 70)	<b>&lt;0.001</b>
PaCO <sub>2</sub>	36 (30, 42)	40 (35, 46)	0.2
<b>Clinical outcomes</b>			
Highest level of supplemental oxygen in the first 3 hours of admission			<b>0.001</b>
HFNC/NRB/NIV	6 (6.2%)	38 (12%)	
Mechanical ventilation	3 (3.1%)	15 (4.5%)	
Nasal Cannula	16 (16%)	107 (32%)	
None	72 (74%)	170 (52%)	
CXR results at admission			<b>&lt;0.001</b>
Bilateral infiltrates	14 (14%)	232 (70%)	
Clear	47 (48%)	36 (11%)	
Not specified	6 (6.2%)	0 (0%)	
Other	11 (11%)	56 (17%)	
Pleural effusion	0 (0%)	6 (1.8%)	
Unilateral infiltrates	19 (20%)	0 (0%)	
ARDS diagnosis	0 (0%)	111 (34%)	<b>&lt;0.001</b>
Respiratory co-infection	41 (42%)	57 (17%)	<b>&lt;0.001</b>

<sup>1</sup> Statistics presented: median (IQR); n (%)<sup>2</sup> Statistical tests performed: Wilcoxon rank-sum test; Fisher's exact test; Fisher's test with simulated p-value; chi-square test of independence